INFLAMMATORY BOWEL DISEASE (IBD)

The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBDs) are chronic gut conditions linked to changes in the intestinal microbiota, especially the loss of helpful bacteria and an increase in harmful ones like Enterobacteriaceae, a group within the Proteobacteria family. This overgrowth of Enterobacteriaceae, including certain strains of Escherichia coli, may worsen inflammation in IBD by thriving in the inflamed gut environment where factors like higher nitrate, oxygen, and altered bile acids support their growth.

Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease
This review discusses how the mucus layer in the intestines, which acts as a protective barrier, is often damaged in inflammatory bowel diseases (IBD) like ulcerative colitis. The authors explain that this weakened barrier allows harmful bacteria to reach the gut lining, triggering inflammation and disease progression. They explore various strategies to strengthen the mucus barrier, including using short-chain fatty acids, prebiotics, probiotics, and certain medications. The review suggests that enhancing the mucus barrier could be a promising approach to treating IBD.